Hope for young CF patients: new drug may ease sinus troubles

NCT ID NCT05581056

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looked at 27 children aged 6 to 11 with cystic fibrosis who were starting treatment with CFTR modulators (Kaftrio). The goal was to see if the drug improves nose and sinus symptoms and quality of life after one year. Researchers used a special questionnaire called SN-5 to measure changes. The study is complete, and results may help confirm whether these drugs help with sinus issues in younger children.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

CFTR modulators (Kaftrio)

What this could lead to

If successful, this could show that CFTR modulators improve nose and sinus symptoms and quality of life in young children with cystic fibrosis.

What could go wrong

This is a small, completed study with only 27 participants, so results may not apply to all children. The treatment is already approved for older ages, but its effect on nasal symptoms in this age group is still uncertain.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cystic fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hôpital Femme Mère Enfant

    Bron, Rhone, 69500, France